Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:526-533
Published online before print January 22, 2004, doi: 10.1161/01.ATV.0000118276.87061.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
24/3/526    most recent
01.ATV.0000118276.87061.00v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kontush, A.
Right arrow Articles by Chapman, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kontush, A.
Right arrow Articles by Chapman, M. J.
Related Collections
Right arrow Lipid and lipoprotein metabolism
Right arrow Oxidant stress
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:526.)
© 2004 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Antioxidative Activity of HDL Particle Subspecies Is Impaired in Hyperalphalipoproteinemia: Relevance of Enzymatic and Physicochemical Properties

Anatol Kontush; Eliana Cotta de Faria; Sandrine Chantepie; M. John Chapman

From the Dyslipoproteinemia and Atherosclerosis Research Unit (U.551) (A.K., S.C., M.J.C.), National Institute for Health and Medical Research (INSERM), Pavillon Benjamin Delessert, Hôpital de la Pitié, Paris, France; and the School of Medicine (E.C.d.F.), Campinas University Hospital, Campinas, Brazil.

Correspondence to Dr Anatol Kontush, INSERM Unité 551, Pavillon Benjamin Delessert, Hôpital de la Pitié, 83 boulevard de l’Hôpital, 75651 Paris Cedex 13, France. E-mail kontush{at}chups.jussieu.fr

Objective— Hyperalphalipoproteinemia (HALP) is characterized by elevated plasma levels of high-density lipoprotein (HDL) particles with altered composition, metabolism, and function. The impact of such modification on antioxidative activities of HDL subfractions is indeterminate.

Methods and Results— Gradient fractionation revealed that buoyant HDL2b and 2a and small dense HDL3b and 3c levels were elevated up to 2.0-fold in HALP subjects (n=9; mean plasma HDL cholesterol, 79 mg/dL) with low hepatic lipase activity. HDL2a, 3a, 3b, and 3c displayed lower specific antioxidative activity (sAA) during low-density lipoprotein (LDL) oxidation (-15% to -86%, on a unit particle mass basis) than their normolipidemic counterparts (n=13). LDL oxidation was delayed by control HDL3a, 3b, and 3c (up to -79%) but specifically by HDL3c (-54%) in HALP. Paraoxonase activity was deficient in all HALP HDL subfractions. Paraoxonase, PAF-AH, and LCAT activities together accounted for {approx}50% of variation in sAA. Abnormal chemical composition of HDL3b and 3c (cholesterol-deficient, triglyceride-enriched) in HALP was associated with impaired sAA. Systemic oxidative stress (as plasma 8-isoprostanes) tended to be elevated (1.5-fold) in HALP and negatively correlated with sAA (as TBARS).

Conclusions— Intrinsic antioxidative activity of HDL subspecies is impaired in HALP, reflecting altered enzymatic and physicochemical properties.


Key Words: oxidative stress • HDL particle heterogeneity • LDL oxidation • lipid hydroperoxides • atherosclerosis




This article has been cited by other articles:


Home page
Diabetes CareHome page
R. S. Rosenson, D. A. Wolff, A. L. Huskin, I. B. Helenowski, and A. W. Rademaker
Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome
Diabetes Care, August 1, 2007; 30(8): 1945 - 1951.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Kontush and M. J. Chapman
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
I. O. Ottestad, B. Halvorsen, T. R. Balstad, K. Otterdal, G. I. Borge, F. Brosstad, A. M. Myhre, L. Ose, M. S. Nenseter, and K. B. Holven
Triglyceride-Rich HDL3 from Patients with Familial Hypercholesterolemia Are Less Able to Inhibit Cytokine Release or to Promote Cholesterol Efflux
J. Nutr., April 1, 2006; 136(4): 877 - 881.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. H.E.M. Klerkx, K. E. Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S.G. Stroes, J. J.P. Kastelein, and J. A. Kuivenhoven
Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels: Pathways by Which Modulation of CETP Activity May Alter Atherogenesis
Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 706 - 715.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Hansel, P. Giral, E. Nobecourt, S. Chantepie, E. Bruckert, M. J. Chapman, and A. Kontush
Metabolic Syndrome Is Associated with Elevated Oxidative Stress and Dysfunctional Dense High-Density Lipoprotein Particles Displaying Impaired Antioxidative Activity
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4963 - 4971.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. M. Herrington and J. S. Parks
Estrogen and HDL: All that Glitters Is not Gold
Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1741 - 1742.
[Full Text] [PDF]